CD47 and myelodysplastic syndrome: Moreover, a new risk stratification paradigm consisting of PDCD1, TIGIT, CD47, and KIR3DL2 expression and the standard risk stratification based on IPSS-R could provide more precise prognosis predictions for MDS.